An Elevated Value of Troponin I, Troponin T, CK-MB, and/or Myoglobin
Troponin I or T is now widely used over other markers for acute MI in the absence of other markers.
Any elevation can indicate myocyte damage; interpret results with defined institutional cutoffs for myocardial infarction.
Suggested Additional Lab Testing
Appropriate follow-up testing with troponin level.
Test as appropriate to rule out causes of increased troponin not caused by cardiac ischemia.
If ECG is abnormal in the presence of positive markers, this is strongly indicative for AMI.
If ECG is normal or shows a pattern not indicative for AMI with a suggestive clinical picture for MI, do serial testing for troponin pressure sensation within the chest with appropriate radiation of pain, which is suggestive of AMI.
Rule out other potential causes of an elevated troponin.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Do Oral Contraceptives Actually Increase Breast Cancer Risk?
- Pancreatitis and the Risk of Cancer
- FDA Approves Olaparib for BRCA-Positive Breast Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- Cabozantinib May Improve Survival Outcomes in Relapsed Hepatocellular Carcinoma
- PEGPH20 Plus mFOLFIRINOX Worsens OS Among Patients With Pancreatic Cancer
- Gemcitabine Plus S-1 May Be Non-inferior to Standard Therapy for Biliary Tract Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances